AKT1 and acute lymphoblastic leukemia: Less frequently, aberrant hyperactivation of the pathway due to gain-of-function mutations in PI3K regulatory (p85) and catalytic subunits (p110) (4, 5% of T-ALL cases) or in AKT (2, 3% cases) have also been reported [86].